二甲双胍与多发性骨髓瘤相关研究进展

Advances in research on metformin and multiple myeloma

多发性骨髓瘤是原发于骨髓的一种血液系统恶性疾病,多发生于老年人,疾病预后往往不佳。硼替佐米联合激素的治疗等可使多发性骨髓瘤患者的预后有所改善。文章介绍多发性骨髓瘤的发病机制及相关诊疗,论述二甲双胍在多发性骨髓瘤治疗中的机制及进展,并提出二甲双胍可能作为多发性骨髓瘤的辅助用药与硼替佐米等化疗药物协同发挥抗肿瘤作用,为多发性骨髓瘤的治疗方案提供一种新的思路。

Multiple myeloma is a malignant disease of the blood system originating from the bone marrow,mainly occurring in the elderly,with poor prognosis and a median survival of 3-4 years.Bortezomib combined with hormone therapy has improved the prognosis of patients with multiple myeloma.This paper briefly introduces the pathogenesis and related diagnosis and treatment of multiple myeloma by referring to relevant literature and materials,discusses the mechanism and current progress of metformin in the treatment of multiple myeloma,and proposes that metformin may play an anti-tumor role in combination with bortezomib and other chemotherapy drugs for multiple myeloma,providing a new idea for the treatment of multiple myeloma.